Research on Parkinson's disease and its treatment. Covers mitochondrial protection, genetic progression markers, antibody therapies, and disease costs.
Researchers identify pedunculopontine nucleus as key brain region in Parkinson's disease-related gait disorders. Targeting acetylcholine-producing nerve cells may alleviate falls and improve walking abilities.
Researchers at Gladstone Institutes establish a connection between brain circuits and Parkinson's disease symptoms, identifying a potential treatment strategy. By activating specific pathways, they can mimic Parkinson's-like symptoms and even restore motor function in mice with dopamine deficiency.
The Parkinson's Disease Foundation has announced $1.2 million in research awards to support scientists studying the cause of and potential treatments for Parkinson's disease. Funding will go towards projects exploring dopamine regulation, tobacco compounds, and more.
A study published in Neuron reveals that the loss of Nna proteins causes mitochondrial dysfunction, leading to severe cell death in mice and fly models. Researchers believe this discovery could provide insights into human neurodegenerative disorders like Parkinson's disease.
Researchers found that Parkinson's patients with impulsive-compulsive spectrum behaviors have impaired self-control, but normal motivation. They prefer smaller immediate payments over larger delayed ones.
A study published in Neurology found that a combination of tests can predict falls in people with Parkinson's disease. The tests evaluated overall symptoms, balance, and mobility, showing a sensitivity of 78% and specificity of 84%. Implementing these tests can help identify those at risk of falling and prevent injuries.
Researchers at Rhode Island Hospital tested spinal cord stimulation in a single patient with Parkinson's disease, finding that low-frequency SCS worsened symptoms while high-frequency SCS improved motor function. Further studies are needed to confirm these findings and explore potential benefits of this approach for PD patients.
A study found that genetic mutations and pesticide exposure interact to increase men's risk for Parkinson's disease. Individuals with two variant alleles of the ABCB1 gene who were exposed to organochlorine insecticides had a stronger association with Parkinson's disease.
A major study found that patients with Parkinson's disease respond similarly to deep brain stimulation (DBS) at two different brain targets, challenging current beliefs. Motor symptoms such as tremor and stiffness improved equally in both groups.
A major study published in the New England Journal of Medicine has found that deep brain stimulation (DBS) is an effective treatment for Parkinson's disease, with similar improvements in motor function regardless of the targeted region. The study also revealed small differences in non-motor effects such as mood and cognitive function.
Researchers have developed a real-time wireless monitoring system to track vital signs of patients with debilitating conditions like Parkinson's disease and COPD. The system uses wearable sensors and a web portal for medical personnel to receive alerts in case of life-threatening events.
Researchers identified a previously unknown brainstem pathway in vertebrates, which stimulates neural activity and locomotion. This finding suggests new research directions for treating Parkinson's disease, particularly targeting the neurotransmitter acetylcholine.
A randomized trial found that pramipexole significantly improved depressive symptoms and functioning in patients with mild-to-moderate Parkinson's disease. The study also showed that the antidepressant effect of pramipexole was largely independent of its effect on motor symptoms.
Researchers successfully transplanted endometrial stem cells into the brains of mice with a Parkinson-like condition, restoring partially dopamine levels. This finding raises the possibility of women serving as their own stem cell donors and banks being established for men and women with Parkinson's disease.
Researchers at Yale University have discovered that endometrial stem cells can repair brain cells damaged by Parkinson's disease, potentially treating women with the condition. The study, published in Journal of Cellular and Molecular Medicine, found that these stem cells can differentiate into dopamine-producing nerve cells.
Researchers at UCSF have created a transgenic mouse model that displays the earliest signs of Parkinson's disease, including constipation and gastrointestinal problems. The model is significant as it validates a theory suggesting the neurological component of Parkinson's is a late-stage effect of a larger systemic problem.
A recent study published in The Lancet Neurology found that deep brain stimulation improves quality of life, mobility, and activities of daily living in advanced Parkinson's disease patients, while also reducing dyskinesia and off time. However, the procedure carried a higher risk of serious adverse events.
Researchers at the Genome Institute of Singapore have developed a zebrafish model to study Parkinson's disease, which can aid in drug development and screening. The model demonstrates that zebrafish can be used to study human diseases, including PD, and has potential for large-scale drug screening.
Parkin and PINK1 genes play a critical role in Parkinson's disease. The study found that PINK1 is rapidly degraded under healthy conditions, but its accumulation stabilizes at low membrane potential. Parkin is recruited to mitochondria with low potential to dispose of damaged organelles.
A new book by NASA climatologist Claire Parkinson examines the coming climate crisis, drawing on 4.6 billion years of Earth's climate history. The book highlights the limitations of computer models and warns of unintended consequences of geoengineering, instead advocating for alternative approaches to reduce climate change.
New data from the RECOVER study showed that Neupro (Rotigotine Transdermal System) effectively improved both motor and non-motor symptoms of Parkinson's disease, including sleep quality, mood, cognition, and pain. The treatment also translated into significant improvements in quality of life for patients.
New data presented at the American Academy of Neurology annual meeting showed that patients with moderate to severe RLS using rotigotine achieved sustained improvements in symptoms over 5 years. The study confirmed the safety and efficacy of rotigotine, with over a third of patients remaining symptom-free after 5 years.
Scientists at the Max Planck Institute of Neurobiology have demonstrated using a new animal model that nerve cells do not begin to die until three conditions are met in Parkinson's disease. This finding is an important step forward in understanding this illness and may offer a potential new direction for therapy.
Scientists at UCSF have developed a novel cell-based strategy to treat Parkinson's disease by transplanting embryonic neurons into the striatum, improving motor function and balance in rats. The approach may offer a more precise effect than traditional strategies and has implications for other neurodegenerative diseases.
A new guideline recommends treatments to help people with Parkinson's disease manage sleep disorders, constipation and sexual problems. The guideline suggests medications like sildenafil citrate and isosmotic macrogol to improve erectile dysfunction and constipation.
A study of over 305,000 people found that those who smoked for 40+ years were 46% less likely to develop Parkinson's disease. However, the risk did not decrease with the number of cigarettes smoked per day.
University of Alabama scientists find that ampicillin enhances the normal function of torsinA protein in cells affected by dystonia and Parkinson's disease. The drug restored normal movement to mice and improved cellular protection against stress, leading to potential new treatments for these debilitating conditions.
People with Parkinson's disease struggle to recognize emotions in others' faces and voices. Deep brain stimulation appears to exacerbate this issue, particularly with fear and sadness expressions.
A study of 136,474 participants found that regular ibuprofen users were 40% less likely to develop Parkinson's disease. Higher doses of ibuprofen also showed a reduced risk of developing the disease.
Researchers at McGill University discover a molecular link between Parkinson's disease and impaired nerve cell communication. They found that parkin protein binds to endophilin-A, affecting synaptic transmission and potentially leading to dopamine neuron death.
A population-based study confirms exposure to TCE increases the risk of Parkinson's disease, with workers five and a half times more likely to develop the condition than those not exposed. The study used twins to evaluate environmental risk factors and found significant associations between TCE exposure and Parkinson's disease.
Research reveals that people with Parkinson's disease are often isolated and stigmatized based on their communication style. The study shows that negative perceptions of speech patterns can limit opportunities for social interaction and reduce full participation in society.
Researchers are testing whether simulation driving can improve Parkinson's patients' driving skills and reduce their threefold increased risk of car accidents. The five-week training program involves simulator-based driving tests and on-road evaluations to assess the impact of cognitive-improving activities.
Parkinson's disease is more common in the Midwest and Northeast, with twice as likely to affect whites and Hispanics compared to blacks and Asians. Environmental factors, such as chemical exposure in farming and agriculture, are considered a major contributor to the disease.
Researchers at Emory University School of Medicine have identified a novel compound, 7,8-dihydroxyflavone, that mimics the brain's growth factor and protects against neurological disease damage. The flavonoid compound shows potential as a new class of brain-protecting drugs with low chronic toxicity.
A large-scale population-based study found that specific sub-class of dihydropyridine cardiovascular medications decreased the risk of Parkinson's disease by 26-30%. The study suggests that these medications' ability to cross the blood-brain barrier may be key to their neuroprotective effects.
Researchers developed a brain-based model to understand how Parkinson's affects learning and attention, highlighting the role of dopamine in non-motor symptoms. The study shows that dopamine medications enhance attentional performance in patients.
Treadmill training can improve walking movements and reduce gait hypokinesia in Parkinson's patients. The systematic review found positive effects on walking speed, stride length, and walking distance but no improvement in cadence.
A study reveals a genetic variant that increases the risk of Parkinson's disease, affecting vitamin B6 metabolism and dopamine production. This interaction with dietary habits may aid in developing individualized therapies.
Researchers found that pathological gamblers with Parkinson's Disease exhibited poor decision-making and abnormal social behavior. They performed poorly in the Iowa Gambling Task and showed difficulties in forming close relationships.
Researchers identified dopamine agonist withdrawal syndrome (DAWS) in patients with Parkinson's disease who reduced their medication dosage. DAWS causes anxiety, panic attacks, depression, and other symptoms that are not alleviated by other treatments.
A study using positron emission tomography (PET) brain scans identified different forms of Parkinsonism with high accuracy. The research found that image-based classification had excellent specificity and positive predictive value for idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
A large-scale study demonstrates that transplanted cells produced dopamine, leading to improved motor symptoms and brain function. Long-term clinical outcomes revealed sustained improvements over a four-year period.
Researchers discovered four small molecules capable of protecting cells from alpha-synuclein toxicity, a hallmark of Parkinson's disease. The compounds improved protein trafficking and decreased mitochondrial damage in multiple models, suggesting potential therapeutic avenues for the disease.
Scientists have found that activating Retinoid X Receptor (RXR) increases dopamine cell survival in models of Parkinson's disease, providing a novel strategy for treating the condition. The study used two cellular models to explore the neuroprotective function of RXR ligands LG268 and XCT.
Researchers studied gait to identify physical signs of Parkinson's disease in its early stages. The team found that people with Parkinson's had significantly asymmetrical arm swings compared to those without the disease.
Researchers at the Muhammad Ali Parkinson Center are conducting a study to determine if simple exercise can help protect neurons in the brain from Parkinson's disease. Participants will follow a structured exercise program called pole-striding, which involves walking with ski-like poles, for 12 weeks.
Researchers found that ghrelin is protective of dopamine neurons and can slow the development of Parkinson's disease. Ghrelin supplementation in mice showed increased dopamine production and reduced loss compared to controls.
Dr. Larisch's research links Parkin and ARTS proteins to excess brain cell death in PD, a progressive neurodegenerative disorder. This discovery may lead to better treatment of patients suffering from Parkinson's Disease.
Scientists at Garvan Institute of Medical Research developed a mathematical model and microscopy method to reveal mechanisms behind dopamine release. The study found that dopamine release is regulated by factors such as the frequency of nerve impulses, making it possible to develop more effective treatments.
ISU researchers have discovered a compound that neutralizes the cell-killing kinase-C and allows dopamine-producing cells to survive and function. This finding brings hope for a possible cure for Parkinson's disease by targeting the protein responsible for killing these cells.
Stereotactic radiosurgery is an effective and safe method for eliminating tremors caused by Parkinson's disease and essential tremor. Long-term results show that SRS favorsably compares to deep brain stimulation and radiofrequency treatments in terms of tremor relief and complications.
Researchers found that simvastatin reverses biochemical changes caused by Parkinson's disease in mice. The drug blocks the activity of p21Ras protein and protects neurons, normalizing neurotransmitter levels and improving motor functions.
A new study found that carriers of Gaucher disease face a significantly higher risk of developing Parkinson's disease, with the risk being 5 times greater than the general public. The study also found that GBA alterations increase the likelihood of early disease onset.
Researchers from Yerkes National Primate Research Center are presenting on various topics, including Alzheimer's disease, Parkinson's disease, and memory function. The study aims to improve human health by understanding the evolutionary specializations of the human brain and its relationship with neurological disorders.
Michigan State University has been awarded a $6.2 million Morris K. Udall Center of Excellence for Parkinson's disease research grant. The grant makes MSU's College of Human Medicine a major player in research of the degenerative disease, with eight investigators expected to join the center by next summer.
Scientists found that Parkinson's disease progresses more slowly in participants with the highest levels of urate. This discovery supports the idea that patients and doctors may be able to better predict the course of the illness.
Higher urate levels in patients with early Parkinson's disease are associated with slower clinical decline. The study found that elevated urate levels in the cerebrospinal fluid were inversely related to disease progression.
A study funded by NIH found that individuals with higher urate levels in their blood and cerebrospinal fluid have a slower rate of disease progression. A clinical trial is underway to examine the safety and benefits of supplemental urate elevation for recently diagnosed patients.
Research identifies opposing roles for phosphorylated alpha-synuclein amino acids in Parkinson's disease. Phosphorylation at Tyr125 protects nerve cells from alpha-synuclein toxicity, whereas Ser129 phosphorylation increases toxic oligomers.